Chefarzt Gynäkologie und Direktor des Departements Frauen und Kinder, Kantonsspital Baden
Dr. med. Martin Heubner
Martin Heubner ist seit 2016 Chefarzt für Gynäkologie und Direktor des Departements Frauen und Kinder am Kantonsspital Baden. Nach Beginn seiner klinischen Ausbildung am Klinikum Dortmund war er von 2005–2016 an der Universitätsfrauenklinik Essen tätig, zuletzt als Leitender Arzt für Gynäkologische Onkologie und operative Gynäkologie. Die Habilitation für das Fach Gynäkologie und Geburtshilfe erfolgte 2011, die Ernennung zum ausserplanmässigen Professor 2016. Seine Schwerpunkte liegen unter anderem in der gynäkologischen Onkologie und der operativen Gynäkologie, hier vor allem der minimalinvasiven Chirurgie sowie roboterassistierten Operationsverfahren. Er trägt den Schwerpunkttitel Gynäkologische Onkologie und absolvierte ein Studium zum Master of Health Business Administration, MHBA.
Literatur
| Nr. | Titel | Autor | Journal | Volume | Seiten | Jahr |
|---|---|---|---|---|---|---|
| [01] | Evaluation of a novel ELISA for the tumorassociated antigen CA 72-4 in patients with ovarian cancer. | Buderath P, Kasimir-Bauer S, Aktas B, Rasch J, Kimmig R, Zeller T, Heubner M | Future Sci. | FSO145 | 2016 | |
| [2] | Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer | Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA | N Engl J Med | 375(22) | 2154-2164 | 2016 |
| [3] | Intraoperative Navigation in Robotically Assisted Compartmental Surgery of Uterine Cancer by Visualisation of Embryologically Derived Lymphatic Networks With Indocyanine-Green (ICG) | Kimmig, R, Aktas B, Buderath P, Rusch P, Heubner M | Journal of Surgical Oncology | 2015/2016 | ||
| [4] | Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-Study Group (AGO-GYN8). | Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner ML, Hanker L, Thiel F, Hilpert F. | Gynecol Oncol | 2015 | ||
| [5] | Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy. | Kimmig R, Iannaccone A, Aktas B, Buderath P, Heubner M | Arch Gynecol Obstet | 2015 | ||
| [6] | Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. | du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P | The Lancet Oncology | 2015 | ||
| [7] | Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies: A comparison to PET/CT. | Grueneisen J, Schaarschmidt BM, Heubner M, Suntharalingam S, Milk I, Kinner S, Heubner A, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L | Eur J Radiol | 2015 | ||
| [8] | Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspects. | Heubner M, Wimberger P, Kasimir-Bauer S, Singer BB, Ruf P, Kimmig R, Siffert W. | Arch Gynecol Obstet | 2015 | ||
| [9] | Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results. | Grueneisen J, Schaarschmidt BM, Heubner M, Aktas B, Kinner S, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L | Eur J Nucl Med Mol Imaging | 2015 | ||
| [10] | Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up. | Hoffmann O, Schroer-Zuendorf IA, Kasimir-Bauer S, Oberhoff C, Kimmig R, Heubner M | Arch Gynecol Obstet | 2015 | ||
| [11] | Diagnostic value of diffusion-weighted imaging in simultaneous 18F-FDG PET/MR imaging for whole-body staging of women with pelvic malignancies. | Grueneisen J, Schaarschmidt BM, Beiderwellen K, Schulze-Hagen A, Heubner M, Kinner S, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L. | J Nucl Med | 55(12) | 1930-1935 | 2014 |
| [12] | Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging for Whole-Body Staging in Patients With Recurrent Gynecological Malignancies of the Pelvis: A Comparison to Whole-Body Magnetic Resonance Imaging Alone. | Grueneisen J, Beiderwellen K, Heusch P, Gratz M, Schulze-Hagen A, Heubner M, Kinner S, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L | Invest Radiol | 2014 | ||
| [13] | Definition of compartment-based radical surgery in uterine cancer: radical hysterectomy in cervical cancer as 'total mesometrial resection (TMMR)' by M Höckel translated to robotic surgery (rTMMR). | Kimmig R, Wimberger P, Buderath P, Aktas B, Iannaccone A, Heubner M | World J Surg Oncol | 2013 | ||
| [14] | Definition of compartment-based radical surgery in uterine cancer: modified radical hysterectomy in intermediate/high-risk endometrial cancer using peritoneal mesometrial resection (PMMR) by M Hockel translated to robotic surgery. | Kimmig R, Aktas B, Buderath P, Wimberger P, Iannaccone A, Heubner M | World J Surg Oncol | 11(1) | 198 | 2013 |
| [15] | Definition of compartment based radical surgery in uterine cancer-part I: therapeutic pelvic and periaortic lymphadenectomy by Michael Höckel translated to robotic surgery. | Kimmig R, Iannaccone A, Buderath P, Aktas B, Wimberger P, Heubner M | ISRN Obstet Gynecol | 2013 | ||
| [16] | Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer. | Aktas B, Kasimir-Bauer S, Wimberger P, Kimmig R, Heubner M | Anticancer Res | 33(1) | 329-336 | 2013 |
| [17] | Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow. | Aktas B, Bankfalvi A, Heubner M, Kimmig R, Kasimir-Bauer S. | Mol Clin Oncol | 1(6) | 1049-1054 | 2013 |
| [18] | The haplotype of three polymorphisms in the SATB1 promoter region impacts survival in breast cancer patients. | Heubner M, Kimmig R, Aktas B, Siffert W, Frey UH | Onc Letters | 2007-2012, 2014 | ||
| [19] | Morbidity of Inguinofemoral Lymphadenectomy in Vulval Cancer. | Soliman AA, Heubner M, Kimmig R, Wimberger P | ScientificWorldJournal | 2012: 341253 | 2012 | |
| [20] | Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study. | Hoffmann O, Aktas B, Goldnau C, Heubner M, Oberhoff C, Kimmig R, Kasimir-Bauer S | Anticancer Res | 31(10) | 3623-3628 | 2011 |
| [21] | Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy. | Kuhlmann JD, Schwarzenbach H, Otterbach F, Heubner M, Wimberger P, Worm KH, Kimmig R, Kasimir-Bauer S | Genes Chromosomes Cancer | 50(8) | 598-605 | 2011 |
| [22] | Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy. | Aktas B, Kasimir-Bauer S, Heubner M, Kimmig R, Wimberger P | Int J Gynecol Cancer | 21(5) | 822-830 | 2011 |
| [23] | Circulating 20S proteasome in patients with non-metastasized breast cancer. | Hoffmann O, Heubner M, Anlasik T, Winterhalter M, Dahlmann B, Kasimir-Bauer S, Kimmig R, Wohlschlaeger J, Sixt SU | Anticancer Res | 31(6) | 2197-2201 | 2011 |
| [24] | The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer. | Heubner M, Wimberger P, Dahlmann B, Kasimir-Bauer S, Kimmig R, Peters J, Wohlschlaeger J, Sixt SU | Gynecol Oncol | 120(2) | 233-238 | 2011 |
| [25] | EpCAM-Autoantibody Levels in the course of disease of Ovarian Cancer patients. | Heubner M, Errico D, Kasimir-Bauer S, Herlyn D, Kimmig R, Wimberger P | Med Oncol | 2010 | ||
| [26] | The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms. | Heubner M, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert W | Oncol Res | 18(7) | 343-347 | 2010 |
| [27] | Increase in Circulating MicroRNA Levels in Blood of Ovarian cancer Patients. | Roth C, Kasimir-Bauer S, Heubner M, Pantel K, Schwarzenbach H | Circulating Nucleic Acids in Plasma and Serum | 63-72 | 2010 | |
| [28] | Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer. | Wimberger P, Heubner M, Lindhofer H, Jäger M, Kimmig R, Kasimir-Bauer S | Anticancer Res | 29(5) | 1787-1791 | 2009 |
| [29] | The AA genotype of a L1C G842A polymorphism is associated with an increased risk for ovarian cancer. | Heubner M, Wimberger P, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert W | Anticancer Res | 29(8) | 3449-3452 | 2009 |
| [30] | The haplotype of two FSHR polymorphisms in ovarian cancer - a potential role of ethnology in risk modification. | Heubner M, Riemann K, Otterbach F, Kimmig R, Kasimir-Bauer S, Siffert W, Wimberger P | Gynecol Oncol | 112(3) | 486-489 | 2009 |
| [31] | Prognostic relevance of the AQP5 -1364C>A polymorphism in primary breast cancer. | Kasimir-Bauer S, Heubner M, Otterbach F, Kimmig R, Siffert W, Adamzik M. | Mol Med Rep | 2(4) | 645-650 | 2009 |
| [32] | Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancer. | Heubner M, Wimberger P, Otterbach F, Kasimir-Bauer S, Siffert W, Kimmig R, Nückel H | Int J Biol Markers | 24(4) | 223-229 | 2009 |
| [33] | Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer. | Wimberger P, Heubner M, Otterbach F, Fehm T, Kimmig R, Kasimir-Bauer S | Gynecol Oncol | 107(2) | 331-338 | 2007 |
| Nr. | Titel | Autor | Journal | Volume | Seiten | Jahr |
|---|---|---|---|---|---|---|
| [01] | Spätfolgen der Sectioentbindung: Narbendefekte und Plazentationsstörungen vorbeugen, erkennen, behandeln | Köninger A, Winter A, Rusch P, Heubner M, Mach P, Kimmig R | Der Gynäkologe | 2017 | ||
| [2] | STIC (Serous Tubal Intraepithelial Carcinoma) – eine beunruhigende Zufallsdiagnose | Heubner M | FHA Frauenheilkunde Aktuell | 1 | 36-39 | 2017 |
| [3] | Eine ungewöhnliche Adnexitis | Heubner M, Krischer B | FHA Frauenheilkunde Aktuell | 2 | 27-31 | 2017 |
| [4] | ”Scars and stars” – MRI of Normal Findings and Complications After Cesarean Delivery. | Kaniewska M, Hohl M; Schäffer L, Heubner M, Kubik-Huch RA | MAGNETOM Flash | 69 | 2-7 | 2017 |
| [5] | Gibt es einen Platz für roboterassistierte Chirurgie in der Gynäkologie? | Heubner M | FHA Frauenheilkunde Aktuell | 3 & 4 | 52-55 | 2016 |
| [6] | ICG-gestützte Navigation bei der Chirurgie uteriner Malignome | Kimmig R, Aktas B, Rusch P, Heubner M | Der Gynäkologe | 49 5 | 373-379 | 2016 |
| [7] | Robot-assisted hysterectomy: a critical evaluation | Buderath P, Aktas B, Heubner M, Kimmig R | Robotic Surgery: Research and Reviews | 2 | 51–58 | 2015 |
| [8] | Robotic surgery in der Gynäkologie – Stand und Ausblick | Kimmig R, Aktas B, Heubner M | Gynäkologe | 47 | 184–190 | 2014 |
| [9] | Peritoneale mesometriale Resektion (PMMR) als Kompartiment-basierte Operation. Technik beim „intermediate/high risk“ Endometriumkarzinom | Kimmig R, Buderath P, Aktas B, Heubner M | Gynäkologe | 46 | 751–756 | 2013 |
| [10] | Endometriumkarzinom – operative Strategie und Adjuvanz. Ein möglicher Paradigmenwechsel. | Kimmig R , Aktas B, Heubner M | Gynäkologe | 46 | 339–344 | 2013 |
| [11] | Hormonaktive Ovarialtumoren. | Heubner M, Kimmig R | Gynäkologe | 45 | 352–354 | 2012 |
| [12] | Catumaxomab in the Treatment of Malignant Ascites: the Evidence of its Therapeutic Value. | Wimberger P, Heubner M, Kimmig R | Clinical Medicine Insights: therapeutics, Review | 2 | 481-489 | 2010 |
| [13] | Primitiver neuroektodermaler Tumor des Ovars. | Wimberger P, Heubner M, Wehling M, Nierwetberg D, Kasimir-Bauer S, Kimmig R | Zentralbl Gynaekol 128 | P1.10 | 14-15 | 2006 |